A Phase 4 interventional study of Vortioxetine (tablet) in Parkinson Disease, Idiopathic, Freezing of Gait and Depression Not Otherwise Specified, sponsored by Marianna Amboni. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Marianna Amboni · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The present study involves patients with Parkinson Disease (PD) suffering from freezing of gait (FOG) and depressive symptoms. The main aim of the study is evaluating the efficacy of vortioxetine in reducing moderate/severe FOG not responsive to dopaminergic treatment in patients with PD with depressive symptoms.
Depression and anxiety are common in patients with Parkinson's disease (PD). In PD, several drugs, such as dopamine-agonists, inhibitors of serotonin uptake (SSRI), tricyclic antidepressants (TCAs) and norepinephrine uptake inhibitors (SNRI) are effective in treating depressive symptoms. Recently, a Delphi consensus has concluded that multimodal drugs, like vortioxetine, are good treatment options for depression in PD and an open-label prospective study has shown that the vortioxetine may improve depressive symptoms and cognition in PD patients with major depression Vortioxetine has different mechanisms of action; it is a serotonin transporter (SERT) inhibitor, an antagonist of 5-HT3, 5-HT7, 5-HTID, a partial agonist of 5-HT1B and a full agonist of 5-HT1A. Moreover, despite vortioxetine does not interact significantly with the norepinephrine transporters or dopamine transporters, it has been shown to increase extracellular levels of norepinephrine, dopamine, and non-monoamine neurotransmitters including acetylcholine. These effects are likely related to the interaction between vortioxetine and various serotonin receptors.
Depression and anxiety or panic attacks are commonly associated to freezing of gait (FOG) in PD. FOG is a disabling symptom of parkinsonian syndromes, whose pathophysiology is heterogeneous and partly unclear. The relationship between FOG and dopaminergic treatment is rather complex. Based on response to dopaminergic treatment, FOG may be responsive, unresponsive (or partially responsive) or induced by dopaminergic drugs. FOG, especially unresponsive FOG, is commonly associated with cognitive dysfunction, namely attentional-executive and visuospatial alterations in PD patients. Since FOG episodes might be related to the Off state and/or to dopaminergic underdosing in PD, the first treatment option should be the increase of dopaminergic drugs dose, when possible. FOG episodes that are less responsive or nonresponsive to dopaminergic treatment represent the greatest therapeutic challenge. Beyond dopaminergic pathway, non-dopaminergic networks, i.e. noradrenergic and cholinergic transmission, may play a role in the pathogenesis of FOG. We hypothesize that vortioxetine might be effective in treating FOG by enhancing both monoamine and non-monoamine neurotransmitters.
STUDY DESIGN Clinical evaluation will be performed during optimal on state of patients
VISIT 1:
Standardized gait analysis with wearable sensors:
Patients will be videotaped and assessed with wearable sensors (Opal) while:
A) Performing the Rating Instrument to Assess Festination and Freezing Gait in Parkinsonian Patients (RIAFFGPP) . In RIAFFGPP patients have to:
i. Sit down on a chair set up in front of a door. ii. After 30 s, stand up and walk to a floor mark (40 x 40 cm) iii. Perform within the mark two 360° turns, clockwise (cw) and counter-clockwise (ccw) iiii. Open and walk through the door, turn outside, and come back to the chair
B) Walking forward along a 10 m path during three conditions:
i. self paced velocity ii. fastest as possible without running pace iii. self paced velocity with mental task (seven serial subtraction from 100 - counting aloud)
Cognitive function assessment:
VISIT 2 (Start of treatment, after 14 days ± 3 days from Visit 1)
Enrolled patients will start vortioxetine:
Vortioxetine Schedule:
Vortioxetine 5 mg: once a day after lunch for one week, After one week, Vortioxetine 10 mg once a day
Four weeks after starting medication patients will fill in again a falls diary for the next 2 consecutive weeks
VISIT 3 (after 12 weeks ± 7 days from ):
Standardized gait analysis with wearable sensors (see visit 1)
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's planned enrollment of 40 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →This is the only study on the registry with Marianna Amboni as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FOG-PD will receive vortioxetine
Drug: Vortioxetine (tablet)
Vortioxetine will be used with the aim of treating freezing of gait in subjects with Parkinson Disease and depressive symptoms
Change in the score of the Freezing Of Gait (FOG) Questionnaire referred to the "on state"
Total score of FOG Questionnaire ranges from 0 to 24 and higher scores correspond to more severe FOG
Time frame: From enrollment to the end of treatment at 12 weeks
Change on severity of FOG not responsive to dopaminergic treatment in patients with PD.
Change on duration (seconds) of FOG episodes on standardized gait analysis with wearable sensors
Time frame: From enrollment to the end of treatment at 12 weeks
Chenage on frequency of FOG not responsive to dopaminergic treatment in patients with PD.
Change on number of FOG episodes on standardized gait analysis with wearable sensors
Time frame: From enrollment to the end of treatment at 12 weeks
No study locations are listed for this record.
Plan to share: Yes — Clinical and outcome measures
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For 12 months after the completation of the study
Access criteria: contacting Central Contact Person by email on mamboni@unisa.it
Start is estimated for Feb 2025; primary completion for Dec 2026, 22 months later.
Of 42 non-industry phase 4 interventional studies under Parkinson Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 75. This study's planned 22 months is below that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 19 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine